Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, Tamara Poljičanin, Sandra Karanović Štambuk, Hana Brborović, Ognjen Brborović
PLOS ONE, doi:10.1371/journal.pone.0301056
Introduction Patients with diabetes mellitus type 2 and chronic kidney disease (T2DM-CKD) have a 5 times higher risk of developing severe SARS-CoV-2 infection than those without these 2 diseases. The goal of this study is to provide information on T2DM-CKD and COVID-19 outcomes, with an emphasis on the association with anti-diabetic medications.
Methodology Study is designed as a retrospective cohort analysis covering the years 2020 and 2021. Data from the National Diabetes Registry (CroDiab) were linked to hospital data, primary healthcare data, Causes of Death Registry data, the SARS-CoV-2 vaccination database, and the SARS-CoV-2 test results database. Study outcomes were cumulative incidence of SARS-CoV-2 positivity, COVID-19 hospitalizations, and COVID-19 deaths. For outcome predictors, logistic regression models were developed.
Results Of 231 796 patients with diabetes mellitus type 2 in the database, 7 539 were T2DM-CKD (3.25%). The 2-year cumulative incidences of all three studies' outcomes were higher in T2DM-CKD than in diabetes patients without CKD (positivity 18.1% vs. 14.4%; hospitalization 9.7% vs. 4.2%; death 3.3% vs. 1.1%, all p<0.001). For COVID-19 hospitalization, protective factors were SGLT-2 inhibitors use (OR 0.430; 95%CI 0.257-0.719) and metformin use (OR 0.769; 95% CI 0.643-0.920), risk factors were insulin use (1.411;) and sulfonylureas use (OR 1.226;. For SARS-CoV-2 positivity
Supporting information
S1
References
Agrawal, Azcoaga-Lorenzo, Fagbamigbe, Vasileiou, Henery et al., Association between multimorbidity and mortality in a cohort of patients admitted to hospital with COVID-19 in Scotland, J R Soc Med,
doi:10.1177/01410768211051715Antoljak, Erceg, Značaj digitalizacije podataka prijave uzroka smrti za unapređenje kvalitete epidemiolos ˇkog nadzora [Role of digitalized death reports in epidemiological surveillance quality, Med. inform
Astrazeneca, Forxiga approved in the EU for the treatment of chronic kidney disease in patients with and without type-2 diabetes
Banerjee, Stoian, Silva-Nunes, Sonmez, Rizvi et al., The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism, Expert Opin Drug Saf,
doi:10.1080/14740338.2021.1970744Belančić, Kresović, Dijan, Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?, Clin Obes,
doi:10.1111/cob.12439Bornstein, Rubino, Khunti, Mingrone, Hopkins et al., Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587%2820%2930152-2Cai, Liu, Sun, He, Zheng et al., Prediabetes and the risk of heart failure: A metaanalysis, Diabetes Obes Metab,
doi:10.1111/dom.14388Capak, Kopal, Benjak, Cerovečki, Draus ˇnik Z ˇ et al., Surveillance system for coronavirus disease 2019 epidemiological parameters in Croatia, Croat Med J,
doi:10.3325/cmj.2020.61.481Ceriello, Catrinoiu, Chandramouli, Cosentino, Dombrowsky et al., Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management, Cardiovasc Diabetol,
doi:10.1186/s12933-021-01408-1Ceriello, Schnell, COVID-19: Considerations of Diabetes and Cardiovascular Disease Management, J Diabetes Sci Technol,
doi:10.1177/1932296820930025Chen, Chen, Chen, Chen, Yang et al., Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic, J Chin Med Assoc,
doi:10.1097/JCMA.0000000000000354Chen, Lv, Lin, Arshad, Dai, The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis, Front Endocrinol,
doi:10.3389/fendo.2022.895458Chudasama, Zaccardi, Gillies, Razieh, Yates et al., Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K, BMC Infect Dis,
doi:10.1186/s12879-021-06600-yClark, Jit, Warren-Gash, Guthrie, Wang et al., Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study, Lancet Glob Health,
doi:10.1016/S2214-109X%2820%2930264-3Cunningham, Carinci, Brillante, Leese, Mcalpine et al., Core Standards of the EUBIROD Project. Defining a European Diabetes Data Dictionary for Clinical Audit and Healthcare Delivery, Methods Inf Med
Dalan, Ang, Tan, Fong, Tay et al., The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study, Eur Heart J Cardiovasc Pharmacother,
doi:10.1093/ehjcvp/pvaa098Emami, Javanmardi, Pirbonyeh, Akbari, Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis, Arch Acad Emerg Med
Extance, Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?, BMJ,
doi:10.1136/bmj.m1174Ferrannini, Lund, Benson, Rizzo, Almahmeed et al., Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis, Eur Heart J Cardiovasc Pharmacother,
doi:10.1093/ehjcvp/pvac044Fried, Schmedt, Folkerts, Bowrin, Raad et al., High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database, Nephrol Dial Transplant,
doi:10.1093/ndt/gfac140Ganesh, Randall, Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis, Br J Clin Pharmacol,
doi:10.1111/bcp.15258Gerdes, Mu ¨ller, Wolf, Busch, Nephroprotective Properties of Antidiabetic Drugs, J Clin Med,
doi:10.3390/jcm12103377Girgin, Aksun, Tu ¨zen As, Şencan, Şanlı et al., Effects of comorbidities associated with COVID-19 cases in Intensive Care Unit on mortality and disease progression, Eur Rev Med Pharmacol Sci,
doi:10.26355/eurrev%5F202304%5F32174Gupta, Marzook, Ahmad, Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview, Clin Exp Med,
doi:10.1007/s10238-022-00821-4Hariyanto, Intan, Hananto, Putri, Kurniawan, Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2021.109031Henry, Lippi, Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Int Urol Nephrol,
doi:10.1007/s11255-020-02451-9Kan, Zhang, Han, Xu, Ye et al., Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis, Front Endocrinol,
doi:10.3389/fendo.2021.708494Katsiki, Ferrannini, Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?, J Diabetes Complications,
doi:10.1016/j.jdiacomp.2020.107723Khunti, Aroda, Bhatt, Bozkurt, Buse et al., Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence, Diabetes Obes Metab,
doi:10.1111/dom.14805Khunti, Knighton, Zaccardi, Bakhai, Barron et al., Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587%2821%2900050-4Koncar, Gvozdanović, Primary healthcare information system-the cornerstone for the next generation healthcare sector in Republic of Croatia, Int J Med Inform,
doi:10.1016/j.ijmedinf.2005.08.007Lai, Gigante, Pellicano, Mariani, Iannazzo et al., Kidney dysfunction is associated with adverse outcomes in internal medicine COVID-19 hospitalized patients, Eur Rev Med Pharmacol Sci,
doi:10.26355/eurrev%5F202303%5F31809Lamprea-Montealegre, Madden, Tummalapalli, Chu, Peralta et al., Prescription Patterns of Cardiovascular-and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease, Diabetes Care,
doi:10.2337/dc22-0614Machado-Duque, Gaviria-Mendoza, Valladales-Restrepo, Franco, De et al., Treatment patterns of antidiabetic and kidney protective therapies among patients with type 2 diabetes mellitus and chronic kidney disease in Colombia. The KDICO descriptive study, Diabetol Metab Syndr,
doi:10.1186/s13098-023-01126-6Martı ´n Sa ´nchez, ´nez-Selle ´s, Garcı ´a, Guille ´n, ´guez-Artalejo et al., Insights for COVID-19 in 2023, Rev Esp Quimioter,
doi:10.37201/req/122.2022Narayanan, Naik, Sahoo, Kamalanathan, Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control, World J Virol,
doi:10.5501/wjv.v11.i6.399Nassar, Abosheaishaa, Singh, Misra, Bloomgarden, Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis, J Diabetes,
doi:10.1111/1753-0407.13359Nguyen, Ho, Nguyen, Ho, Li et al., Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis, Metabolism,
doi:10.1016/j.metabol.2022.155196Perez-Gomez, Bartsch, Castillo-Rodriguez, Fernandez-Prado, Fernandez-Fernandez et al., Clarifying the concept of chronic kidney disease for non-nephrologists, Clin Kidney J,
doi:10.1093/ckj/sfz007Permana, Yanto, Hariyanto, Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2022.110205Poljicanin, Lang, Mach, Svajda, Croatian diabetes registry (CroDiab) and implementation of standardised diabetes checklists using Joint Action CHRODIS Recommendations and Criteria, Ann Ist Super Sanita,
doi:10.4415/ANN%5F21%5F01%5F12Poljicanin, Pavlić-Renar, Metelko, CroDiab NET-registar osoba sa s ˇećernom bolesti [CroDiab NET-electronic diabetes registry, Acta Med Croatica
Poljičanin, Pristas, National public health information system in Croatia
Qu, Zheng, Wang, Li, Liu et al., The potential effects of clinical antidiabetic agents on SARS-CoV-2, J Diabetes,
doi:10.1111/1753-0407.13135Salmen, Pietroșel, Mihai, Bica, Teodorescu et al., Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19, Biomedicines,
doi:10.3390/biomedicines10102624Schernthaner, Shehadeh, Ametov, Bazarova, Ebrahimi et al., Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes, Cardiovasc Diabetol,
doi:10.1186/s12933-020-01154-wVergara, Rossi, Biagi, Falasconi, Pannone et al., Role of comorbidities on the mortality in patients with SARS-CoV-2 infection: an Italian cohort study, Minerva Med,
doi:10.23736/S0026-4806.21.07187-1
